On April 4, 2022 CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, reported that management will be presenting a corporate overview at the 21st Annual Needham Virtual Healthcare Conference being held April 11 – 14, 2022 (Press release, CorMedix, APR 4, 2022, View Source [SID1234611431]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

21st Annual Needham Virtual Healthcare Conference
Date: Tuesday, April 12, 2022
Time: 11:00am EDT
Webcast Link

On April 4, 2022 BIOKÉ reported it has signed a distribution agreement with Applied Cells Inc to distribute the MARS technology in the Netherlands, Belgium, and Luxembourg (Benelux), effective immediately (Press release, Applied Cells, APR 4, 2022, View Source;utm_medium=rss&utm_campaign=bioke-to-distribute-applied-cells-cell-prep-isolation-system-in-benelux-countries [SID1234611430]). Applied Cells is a leading provider of cell preparation and isolation solutions for tumor biology, cell therapy, and genomics research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 4, 2022 Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, reported the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies (Press release, Theseus Pharmaceuticals, APR 4, 2022, View Source [SID1234611425]). Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target. Theseus will select hits for potential development into targeted tyrosine kinase inhibitors (TKIs) and will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Screening small-molecule libraries inside living cells—in a physiologically relevant context—is particularly important for success in developing cancer therapeutics," said Nils Hansen, PhD, Chief Executive Officer of Vipergen. "We are excited to apply our in-living-cell DEL screening technology to Theseus’ efforts to develop next-generation kinase inhibitors to transform the way cancer is treated."

On April 4, 2022 Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, reported preliminary results from an ongoing Phase 1 trial evaluating TTX-030 in combination with chemoimmunotherapy for the first-line treatment of patients with locally advanced or metastatic HER2- gastric or gastroesophageal junction (GEJ) cancer will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 taking place in New Orleans, LA, April 8-13, 2022 (Press release, Trishula Therapeutics, APR 4, 2022, View Source [SID1234611424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR Oral Presentation Details:

Title: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the 1st line treatment of locally advanced or metastatic gastric/GEJ cancer.

Abstract Number: 8213

Session Title: Combination Immunotherapy Clinical Trials

Session Date and Time: Tuesday, April 12, 2022, 10:15 to 12:15 p.m., Central Time

Location: Hall B-C, Convention Center

Presentation Number: CT015

On April 4, 2022 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, reported that new preclinical data on the company’s transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Vivace Therapeurtics, APR 4, 2022, View Source [SID1234611423]). Presented findings will highlight results of research evaluating the combination of VT3989 and osimertinib (Tagrisso), an epidermal growth factor receptor (EGFR) inhibitor, in preclinical EGFR mutant tumor models. Study data demonstrated strong synergistic activity for the treatment combination as compared to osimertinib alone, as evidenced by enhanced efficacy and delayed tumor regrowth. The AACR (Free AACR Whitepaper) conference is being held April 8-13, 2022, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vivace’s proprietary compounds inhibit palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. The company’s clinical candidate, VT3989, is currently in Phase 1 clinical trials. Pre-clinical research and development activities have demonstrated that the clinical candidate is active as a monotherapy against tumors that rely upon dysfunction of the Hippo pathway, and in combination with other anti-cancer therapies in additional tumor types.

Details of the company’s presentation at the AACR (Free AACR Whitepaper) conference are as follows:

Poster Presentation #5364:

Title: The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models
Presenting Author: Tracy Tang, Ph.D., vice president of biology, Vivace Therapeutics
Date/Time: Friday, April 8, 2022, 12:00 – 1:00 p.m. Central
Location: E-Poster Website